14.62

6.10% +0.84

Stoke Therapeutics Inc (STOK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Stoke Therapeutics Inc stock is currently priced at $14.62, with a 24-hour trading volume of 1.75M. It has seen a +6.10% increased in the last 24 hours and a +32.55% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $13.92 pivot point. If it approaches the $14.79 resistance level, significant changes may occur.

Previous Close:

$13.78

Open:

$13.9

24h Volume:

1.75M

Market Cap:

$761.99M

Revenue:

$8.78M

Net Income/Loss:

$-104.70M

P/E Ratio:

-5.7787

EPS:

-2.53

Net Cash Flow:

$-82.68M

1W Performance:

+1.46%

1M Performance:

+32.55%

6M Performance:

+285.75%

1Y Performance:

+30.54%

1D Range:

$13.90

$14.92

52W Range:

$3.35

$16.66

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name

Stoke Therapeutics Inc

Sector

Healthcare (1198)

Industry

Biotechnology (691)

Phone

781-430-8200

Address

45 Wiggins Avenue, Bedford, MA

Employee

Twitter

@stoketx

Next Earnings Date

2024-06-05

Latest SEC Filings

STOK's Discussions on Twitter

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-01-23	Upgrade	BofA Securities	Underperform → Neutral
Apr-26-23	Resumed	Canaccord Genuity	Buy
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-31-22	Initiated	Jefferies	Buy
Dec-03-21	Initiated	BofA Securities	Buy
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight
May-18-21	Initiated	UBS	Neutral
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy
Dec-11-20	Reiterated	Needham	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-29-20	Resumed	JP Morgan	Neutral
Sep-29-20	Initiated	Needham	Buy
Dec-18-19	Initiated	Wedbush	Outperform
Nov-12-19	Initiated	BTIG Research	Buy
Oct-25-19	Initiated	H.C. Wainwright	Buy
Jul-15-19	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Cowen	Outperform
Jul-15-19	Initiated	Credit Suisse	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight

View All

Stoke Therapeutics Inc Stock (STOK) Latest News

Stoke Therapeutics (NASDAQ:STOK) Trading Up 5.3% - MarketBeat

MarketBeat

It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope - Simply Wall St

Simply Wall St

Stoke Therapeutics Inc [STOK] stock for 769500 USD was sold by Nash Huw M. – Knox Daily - Knox Daily

Knox Daily

This trade activity should not be overlooked: Stoke Therapeutics Inc (STOK) – Sete News - SETE News

SETE News

Financial Fitness Check: Examining Stoke Therapeutics Inc (STOK)'s Key Ratios – DWinneX - The Dwinnex

The Dwinnex

Stoke Therapeutics (NASDAQ:STOK) Shares Down 4% - MarketBeat

MarketBeat

Stoke Therapeutics Inc Stock (STOK) Financials Data

Stoke Therapeutics Inc (STOK) Revenue 2024

STOK reported a revenue (TTM) of $8.78 million for the quarter ending December 31, 2023, a -29.21% decline year-over-year.

Stoke Therapeutics Inc (STOK) Net Income 2024

STOK net income (TTM) was -$104.70 million for the quarter ending December 31, 2023, a -3.59% decrease year-over-year.

Stoke Therapeutics Inc (STOK) Cash Flow 2024

STOK recorded a free cash flow (TTM) of -$82.68 million for the quarter ending December 31, 2023, a -130.78% decrease year-over-year.

Stoke Therapeutics Inc (STOK) Earnings per Share 2024

STOK earnings per share (TTM) was -$2.37 for the quarter ending December 31, 2023, a +8.85% growth year-over-year.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer epilepsy panel testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.